Eton Pharmaceuticals (ETON) Accumulated Expenses (2017 - 2025)

Eton Pharmaceuticals has disclosed Accumulated Expenses across 9 years of filings, most recently posting $9.4 million for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $9.4 million, up 5.54% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.4 million (up 5.54% YoY), and the FY2025 annual result was $9.4 million, up 5.54% from the prior year.
• Accumulated Expenses came in at $9.4 million for Q4 2025 at Eton Pharmaceuticals, up from $9.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.4 million in Q4 2025 to a low of $22000.0 in Q2 2021.
• The 5-year median for Accumulated Expenses is $4.3 million (2022), against an average of $4.4 million.
• Across the five-year window, Accumulated Expenses slumped 99.33% in 2024 and soared 18893.75% in 2025, its largest moves.
• Eton Pharmaceuticals' Accumulated Expenses stood at $1.4 million in 2021, then surged by 168.08% to $3.7 million in 2022, then soared by 47.08% to $5.4 million in 2023, then surged by 65.5% to $8.9 million in 2024, then gained by 5.54% to $9.4 million in 2025.
• The last three Accumulated Expenses figures came in at $9.4 million (Q4 2025), $9.1 million (Q3 2025), and $7.5 million (Q2 2025), per Business Quant data.